• Most common at delivery, but can occur at any time during pregnancy • Mild thrombocytopenia (≥80,000/microL, typically 100,000 to 150,000/microL) •
No increased bleeding or bruising •

No associated abnormalities on CBC •
No fetal or neonatal thrombocytopenia • In 1 percent of cases, preeclampsia can be associated with a constellation of findings including more severe hypertension (often with severe headache and/or visual symptoms), liver function abnormalities and epigastric pain, and thrombocytopenia; this condition has been designated as "preeclampsia with severe features" (table 4) [10, 22] . A platelet count <100,000/microL is a criterion for preeclampsia with severe features (table 4) [15, 22] . Preeclampsia with severe features is also associated with microangiopathic hemolytic anemia with one or more of the following: schistocytes on the blood smear, increased lactate dehydrogenase (LDH), increased bilirubin, and decreased haptoglobin; these features also raise the possibility of thrombotic microangiopathy syndromes such as thrombotic thrombocytopenic purpura. (See 'Thrombotic microangiopathy (TMA)' below.)
The presence of seizures changes the diagnosis to eclampsia. (See "Eclampsia".) HELLP -The name HELLP syndrome has been used for decades; this syndrome may not require the presence of hypertension or proteinuria. By definition HELLP syndrome includes thrombocytopenia and evidence of microangiopathic hemolytic anemia. In a review of case series of women with preeclampsia with severe features/HELLP syndrome, the median nadir platelet counts were 43,000 to 57,000/microL. However, among individual women, the lowest platelet counts were 6000 to 15,000/microL [23] . (See "HELLP syndrome".)
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For patients with hereditary TTP, pregnancy confers a great risk for an acute, severe episode of TTP [24] . For patients in remission from acquired, autoimmune TTP, pregnancy may also increase the risk of relapse, but the frequency is low [25] . For patients with C-TMA, pregnancy and the postpartum period are also a risk for triggering an acute episode of severe acute kidney injury [26] .
The only defining clinical features of the TMA syndromes are microangiopathic hemolytic anemia (MAHA), which is inferred from the presence of schistocytes on the peripheral blood smear (picture 1), and thrombocytopenia, which can be severe (table 5) . Severe acute kidney injury is the most important presenting abnormality in patients with C-TMA. Other findings that may be present include neurologic symptoms ranging from mild headache to seizures and transient focal abnormalities. Although fever has been described as a manifestation of TTP, this was most commonly seen in the pre-plasma exchange era; fever almost always indicates a systemic infection [27] .
The TMA syndromes can occur during any trimester, but they are more commonly seen during late pregnancy or postpartum. Persistence or worsening of thrombocytopenia, MAHA, and ongoing end-organ injury for more than three days after delivery is considered by some experts to be strongly suggestive of a TMA, since preeclampsia with severe features almost always begins to recover before this time.
Despite the overlapping clinical presentations, different TMAs have differing pathophysiologies and require different treatments. TMAs are potentially life-threatening, so it is important to make the most accurate diagnosis possible and in many cases to treat presumptively for the most serious of these while pursuing diagnostic testing. (See "Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Overview of primary TMA syndromes'.)
Many women with TMA during pregnancy deliver healthy term infants. However, intrauterine fetal death may occur from placental infarction caused by thrombosis of the decidual arterioles. These complications are discussed separately. (See "Acquired TTP: Initial treatment", section on 'Acquired TTP during pregnancy' and "Hereditary thrombotic thrombocytopenic purpura (TTP)", section on 'Pregnancy'.) TTP -Thrombotic thrombocytopenic purpura (TTP) is associated with severely reduced activity of ADAMTS13, a protease that cleaves very large von Willebrand factor (VWF) multimers on endothelial cells. ADAMTS13 may be reduced because of a neutralizing autoantibody (acquired, autoimmune TTP) or an inherited mutation in the ADAMTS13 gene (hereditary TTP). (See "Acquired TTP: Clinical manifestations and diagnosis" and "Hereditary thrombotic thrombocytopenic purpura (TTP)".) A significant proportion of patients with hereditary TTP have their first presentation of disease during pregnancy, but acquired TTP is more common than hereditary TTP and thus more likely in a pregnant patient without a family history of TTP. A 2012 series of 42 patients with a first episode of TTP during pregnancy found threefourths were due to acquired TTP and one-fourth to hereditary TTP [24] . A 2014 series of 35 women from the United Kingdom TTP registry who presented with new onset TTP during pregnancy documented acquired TTP in 12 (34 percent) and hereditary TTP in 23 (66 percent) [28] .
Features suggestive of TTP include thrombocytopenia and schistocytes combined with severe neurologic findings (although half of patients with TTP have no or only minor neurologic abnormalities); and absence of features of DIC (eg, absence of coagulation abnormalities). As noted above, TTP can occur during any trimester or postpartum. In a series of 166 pregnancies complicated by TTP, the median onset was at 23 to 24 weeks of gestation, with two-thirds presenting in the first and second trimesters and one-third presenting in the third trimester [29] .
The diagnosis of TTP relies on a thorough clinical assessment combined with a finding of ADAMTS13 activity <10 percent. As in non-pregnant patients, the clinical assessment is vital to the diagnosis, because results of ADAMTS13 activity testing often are not immediately available. In contrast to severe ADAMTS13 deficiency, moderately reduced ADAMTS13 activity (eg, activity between 10 and 50 percent) can be seen in many systemic disorders and is not specific for (or indicative of) TTP. ADAMTS13 activity decreases during pregnancy, related to the increased levels of VWF, and may fall below 50 percent in many pregnant women near term (but not below 10 percent, which is typical of TTP) [30] . These issues are discussed in more detail separately. (See "Acquired TTP: Clinical manifestations and diagnosis", section on 'Reduced ADAMTS13 activity' and "Acquired TTP: Clinical manifestations and diagnosis", section on 'Diagnostic testing' and "Pathophysiology of acquired TTP and other primary thrombotic microangiopathies (TMAs)", section on 'TTP pathogenesis'.)
The clinical course of TTP is not affected by delivery, intravenous immune globulin (IVIG), or eculizumab. The most important treatment is urgent plasma exchange (PEX) therapy, which removes the autoantibody to ADAMTS13 and supplies functional ADAMTS13 in the replacement plasma. For patients known to have hereditary TTP, plasma infusion is sufficient for treatment because it supplies ADAMTS13. Platelet transfusion should be reserved for treatment of severe bleeding in a patient with TTP due to the potential increased risk of thrombosis, but platelets should not be withheld in a bleeding patient due to concerns about this risk. (See "Acquired TTP: Initial treatment", section on 'Initiation of PEX for a presumptive diagnosis of TTP' and "Hereditary thrombotic thrombocytopenic purpura (TTP)", section on 'Pregnancy'.)
With appropriate monitoring and therapy, outcomes for pregnancy-associated TTP are usually successful. In a review of cases from the United Kingdom TTP registry, 10 women known to have hereditary TTP who were actively monitored and treated during pregnancy had 15 live births, and six women with acquired TTP had six pregnancies; there were no maternal or fetal deaths, and all deliveries were in the third trimester [28] .
Complement-mediated TMA -Complement-mediated TMA (C-TMA), also called complement-mediated HUS or "atypical HUS," is a disorder in which patients have increased activation of complement on endothelial cells. We avoid the term atypical HUS because it is nonspecific. Patients with dysregulated complement can develop microthrombi in small vessels throughout the vasculature; the kidney is often affected. Complement may be dysregulated because of a neutralizing autoantibody or an inherited mutation in a complement regulatory gene such as complement factor H (CFH). (See "Acute kidney injury (acute renal failure) in pregnancy" and "Complement-mediated hemolytic uremic syndrome", section on 'Genetic mutations'.)
Many patients with hereditary C-TMA have their first presentation of disease during pregnancy or postpartum. C-TMA presents very similarly to HELLP syndrome and TTP, and the differentiation among C-TMA, HELLP, and TTP can often be challenging. Key diagnostic features include microangiopathic hemolytic anemia, thrombocytopenia, and increasing serum creatinine. ADAMTS13 activity is not severely deficient in C-TMA (activity is ≥10 percent) and stool studies are negative for Shiga toxin-producing organisms. Often, patients with C-TMA are thought to have HELLP syndrome, but instead of improving within one to two days of delivery the patient's clinical status and renal function worsens. Limited data suggest that the platelet count is not severely decreased in C-TMA, and overt neurologic abnormalities are rare. Most patients have severe kidney injury requiring dialysis.
The clinical course of C-TMA is not affected by delivery. In fact, the postpartum period may be the time of greatest risk for the occurrence of C-TMA [26] . The most important treatment is anti-complement therapy to stop the process, and supportive care for renal failure that may include dialysis. Anti-complement therapy (eg, with eculizumab) should be initiated promptly if C-TMA is considered the most likely diagnosis, because end-stage renal disease may occur rapidly if the process goes unchecked. Additional information about anti-complement therapies, including therapies under development, is presented separately. Patients with ST-HUS typically have severe abdominal pain and diarrhea, which is typically overtly bloody, as their major symptom. There may be a history of eating improperly prepared food or a recent outbreak, but almost all cases are sporadic. MAHA and thrombocytopenia are present and often accompanied by renal insufficiency. Fever and neurologic symptoms may also be present but are not always seen. These features are similar to those seen in children, in whom ST-HUS is much more common.
The diagnosis of ST-HUS is made based on clinical features, microangiopathic hemolytic anemia, thrombocytopenia, and demonstration of an implicated diarrheal organism. Stool testing for Shiga toxin-secreting bacteria (eg, E. coli 0157:H7, Shigella dysenteriae) and for Shiga toxin itself should be performed. Most patients will have been tested for and found to have normal or only mildly reduced ADAMTS13 activity and normal or nonspecifically reduced complement levels. Management involves supportive care, similar to children. (See "Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children".)
Causes of thrombocytopenia not triggered by the pregnancy -Some conditions associated with thrombocytopenia are discovered incidentally during the pregnancy. These include systemic lupus erythematosus (SLE), medications that cause immune thrombocytopenia, heparin-induced thrombocytopenia (HIT), cancer, infection, liver disease, hypersplenism, deficiency of vitamin B12/folate/copper, or inherited platelet disorders. Most of these causes of thrombocytopenia are rare during pregnancy, with the exception of SLE, which may be more common than several of the conditions discussed above such as TMAs. These are discussed in separate topic reviews:
DETERMINING THE LIKELY CAUSE(S)
Overview of the evaluation -In many cases, pregnancy imposes additional urgency on determining the cause of thrombocytopenia and additional management decisions related to the potential for complications that may affect the patient and the fetus. The diagnostic evaluation and interventions for the most likely cause(s) of the findings must often be performed simultaneously. Early involvement of experts in high-risk obstetrics, hematology, and other appropriate specialists (eg, nephrology when renal failure is present; infectious diseases when sepsis is suspected) is advised.
Selected causes categorized by trimester and platelet count are shown in the table (table 2) and discussed above. (See 'List of causes' above.) Our approach to distinguishing among these causes, as described in the following sections, is consistent with a 2013 pocket guide on thrombocytopenia in pregnancy and a practice guideline on immune thrombocytopenia (ITP) from the American Society of Hematology and a 2010 international consensus panel [31] [32] [33] . Additional information concerning thrombocytopenic conditions including drug-induced thrombocytopenia, ITP, and thrombotic thrombocytopenic purpura (TTP) can be found on a website maintained and updated by Dr. James N George at the University of Oklahoma Health Sciences Center: www.ouhsc.edu/platelets [34].
As noted above, our approach to the evaluation takes into account the severity of thrombocytopenia, clinical presentation (table 6) • Symptoms of infection such as fever and chills.
• New daily medications within the past three weeks, or occasional medications taken immediately before symptoms occurred.
• Personal or family history of excessive bleeding, bruising, pregnancy complications, or known thrombotic microangiopathy (TMA) syndrome.
• Systemic lupus erythematosus or other autoimmune disorder.
• History of liver disease.
• Timing of the drop in platelet count (which trimester, how rapidly).
• Presence of anemia more severe than expected for the stage of pregnancy.
• Abnormalities of the peripheral blood smear, such as abnormal white blood cells or nucleated red blood cells.
• https://www.uptodate.com/contents/thrombocytopenia-in-pregnancy/print?search=%E8%A1%80%E5%B0%8F%E6%9D%BF%E5%87%8F%E5%B0%91%E7%9 Isolated, asymptomatic thrombocytopenia; platelets >80,000 -Almost all pregnant women with relatively mild or incidentally discovered thrombocytopenia (eg, platelet count between 80,000 and 150,000/microL) without other cytopenias or major clinical findings will have gestational thrombocytopenia (GT). The only other common cause to consider may be ITP; however, ITP with mild thrombocytopenia requires no treatment and therefore the management is observation, as for GT.
Other, uncommon causes of isolated, mild thrombocytopenia include conditions that may have preceded the pregnancy or developed during the pregnancy but remained clinically silent, such as systemic lupus erythematosus (SLE), inherited thrombocytopenia, bone marrow disorders such as myelodysplasia, human immunodeficiency virus (HIV), liver disease, hypersplenism, nutrient deficiencies (eg, vitamin B12, folate, copper), and type II von Willebrand disease. These conditions account for <1 percent of cases. (See 'Causes of thrombocytopenia not triggered by the pregnancy' above.) Evaluation for these conditions includes a personal and family history for bleeding disorders; review of the complete blood count (CBC) for other cytopenias and morphologic abnormalities in white blood cells, red blood cells, and platelets.
Pseudothrombocytopenia due to in vitro platelet clumping can be misinterpreted as true thrombocytopenia. Pseudothrombocytopenia should be excluded by reviewing the blood smear and, if necessary, repeating the platelet count using a tube containing citrate or heparin rather than EDTA as the anticoagulant. This and other testing for causes of thrombocytopenia not directly related to pregnancy are discussed separately. (See "Approach to the adult with unexplained thrombocytopenia".)
HIV testing is appropriate for all patients if not done already. Testing early in each pregnancy is routine in the United States. (See "Prenatal care: Initial assessment", section on 'Human immunodeficiency virus' and "Screening and diagnostic testing for HIV infection", section on 'Routine screening'.)
As noted above, it is not possible (or necessary) to distinguish between GT and ITP during pregnancy as long as the thrombocytopenia is relatively mild (eg, platelet count >80,000/microL). Both of these conditions are diagnosed by excluding other causes of thrombocytopenia; there are no laboratory tests for either condition. GT can present at any time during pregnancy, but because CBCs are more likely to be performed later in the pregnancy, GT is more often recognized near term or at delivery. GT resolves after delivery, but it may require more than six weeks. ITP is often present before, during, and after the pregnancy, and the degree of thrombocytopenia is variable. If the platelet count drops below 80,000/microL, then ITP becomes the more likely diagnosis. If the history and/or examination suggest a cause other than GT or ITP, appropriate testing should be obtained. (See 'List of causes' above.) After delivery, GT will resolve and ITP typically will persist, allowing a presumptive diagnosis to be made in most cases. The value of this is that patients with GT do not require any additional monitoring until or unless they become pregnant again. GT can recur with subsequent pregnancies, so it may be helpful to anticipate this possibility. If thrombocytopenia persists after pregnancy (eg, at the six-week follow-up), then ITP becomes the likely diagnosis. A less common condition such as an inherited platelet disorder may also be responsible. The evaluation, differential diagnosis, and management of ITP are discussed in detail separately. Preeclampsia with severe clinical features and HELLP syndrome (hemolysis, elevated liver function tests, and low platelets) is significantly more common than DIC, and DIC is significantly more common than the TMAs (approximate incidences, 1 in 100, 1 in 1000, and 1 in 100,000, respectively) [35] . (See "Disseminated intravascular coagulation during pregnancy", section on 'Prevalence'.)
In a patient with SLE, it can be challenging (and may not be possible) to distinguish a flare of SLE from preeclampsia with severe features. This evaluation is presented separately. (See "Pregnancy in women with systemic lupus erythematosus", section on 'Preeclampsia versus lupus nephritis'.)
The evaluation to determine the cause includes review of the CBC to assess for other cytopenias (eg, leukopenia, anemia out of proportion to the stage of pregnancy) and the red blood cell indices; review of the peripheral blood smear to detect schistocytes or abnormal white blood cells, prothrombin time (PT) and activated partial thromboplastin time (aPTT), and fibrinogen level; metabolic panel with renal function and hepatic function tests; urinalysis, lactate dehydrogenase (LDH) and bilirubin to assess hemolysis; and, if the PT, aPTT, and/or fibrinogen level are abnormal, D-dimer. At least one additional platelet count measurement should be obtained in order to identify a declining trend (and its tempo).
Features that help to narrow down to the most likely (or most dangerous) cause in the symptomatic or severely thrombocytopenic patient include the following:
The most important diagnostic distinctions to make are between conditions that are treated by delivery and those that are not, especially if the patient is not at term (algorithm 1). If a TMA is considered likely, the major decisions are whether to initiate plasma exchange or anti-complement therapies; a TMA will not resolve with Early communication between the obstetrician, anesthesiologist, and consulting hematologist is advised when there are questions about the diagnosis or possible need for urgent interventions.
MANAGEMENT DECISIONS
Treatment of bleeding or severe thrombocytopenia -The risk of severe bleeding due to thrombocytopenia only increases substantially with platelet counts below 50,000/microL. For women with platelet counts of 50,000 to 100,000/microL, increased bleeding may occur with invasive procedures, but will not occur spontaneously. For women with platelet counts <50,000 and severe bleeding (bleeding into a closed space, bleeding requiring transfusion, bleeding that will not stop) or bleeding that is expected to become severe, platelet transfusion should be given immediately, regardless of the underlying cause of thrombocytopenia. (See "Clinical and laboratory aspects of platelet transfusion therapy", section on 'Actively bleeding patient'.) Platelet transfusions are not appropriate for women without active bleeding, unless surgery and/or delivery is imminent.
The platelet count threshold for a non-bleeding pregnant woman nearing delivery or a procedure depends on the expected mode of delivery or type of procedure. In the absence of bleeding, we use the following thresholds:
The safety of these thresholds is supported by data from a review of 119 pregnancies associated with immune thrombocytopenia (ITP), 17 of 110 women (15 percent) had platelet counts <50,000/microL at delivery [21] . Hemorrhagic complications in these women were uncommon and did not correlate with the platelet count. None of the women with platelet counts <50,000/microL had blood loss greater than one liter; the greatest blood loss was in four women with platelet counts between 54,000 and 321,000/microL. Individuals with other causes of thrombocytopenia that are also associated with platelet dysfunction may require higher platelet counts, and clinical judgement is required to incorporate the cause of thrombocytopenia and the bleeding risk for the specific patient.
If therapy is needed to raise the platelet count in a woman with ITP, glucocorticoids or intravenous immune globulin (IVIG) approximately one week prior to a scheduled delivery. If the platelet count is <20,000 to 30,000/microL at the time of delivery and therapy is needed to raise the platelet count, platelet transfusions should be used. (See 'ITP therapies' below.)
There are no data comparing vaginal delivery versus cesarean delivery for women with ITP, and we reserve cesarean delivery for standard obstetrical considerations [14] . This practice is consistent with guidelines published by the American Society of Hematology, the British Society of Haematology, and an international consensus report [14, 31, 32] . (See "Cesarean delivery: Preoperative planning and patient preparation", section on 'Indications'.)
Both forceps and vacuum-assisted delivery are relatively contraindicated in the setting of severe maternal thrombocytopenia. However, if operative vaginal delivery is performed, we use forceps rather than vacuum-assisted delivery because the potential harms of vacuum-assisted delivery are greater for the fetus than those with forceps if there is fetal thrombocytopenia. The complications of operative vaginal delivery are described in more detail separately.
We do not attempt to measure the fetal platelet count prior to delivery, and we avoid placing a fetal scalp electrode if the maternal platelet count is <80,000/microL. Measurement of the neonatal platelet count may be appropriate in some cases, as described in the next section. (See 'Neonatal testing' below.) Of note, the indications for platelet transfusions in patients with TTP or heparin-induced thrombocytopenia (HIT) are the same as for other women with thrombocytopenia; platelet transfusions should be reserved for bleeding that is clinically important or for prevention of bleeding with an invasive procedure or delivery.
(See "Clinical and laboratory aspects of platelet transfusion therapy", section on 'TTP or HIT'.)
In conditions in which platelets are being destroyed, the increase in platelet count with transfusion will only be temporary, and additional interventions directed at the underlying disorder are also needed:
Frequency of platelet count monitoring -The frequency of platelet count monitoring is greater for those with more severe thrombocytopenia, with the specific interval individualized for the patient and altered as needed depending on the platelet count trend.
The following provides a general guide:
Need for urgent/emergent delivery -The need for delivery depends on the underlying cause, which may not be definitively determined. The most challenging cases are those in which the cause is not entirely clear. In a preterm gestation, as long as mother and fetus appear stable, completing a thorough evaluation before making decisions for delivery is important, as several of the etiologies can be addressed, allowing the pregnancy to safely progress to term. If the mother and/or fetus is unstable, and steps taken for stabilization do not allow a detailed evaluation, then delivery may be the best choice. In such cases, antenatal glucocorticoids should be given prior to delivery if possible (see "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"). At term, delivery may be warranted to facilitate evaluation of the underlying cause more efficiently. • Daily monitoring is appropriate for most patients who are hospitalized due to maternal illness, although women with gestational thrombocytopenia (GT) and mild, stable thrombocytopenia who are hospitalized for an unrelated illness such as hyperemesis or asthma may not need daily platelet counts. Sometimes the frequency can be decreased depending on the patient's level of stability.
• For those with mild to moderate thrombocytopenia, which is likely due to GT, or less commonly to ITP, we generally monitor the platelet count once per trimester or once per month (depending on the absolute platelet count and platelet count trend), and assess the platelet count at 36 to 37 weeks to plan for a possible need for treatment near delivery.
• Routine obstetrical management is appropriate for women with platelet counts >100,000/microL.
Conditions treated by delivery -Thrombocytopenic conditions that are treated by delivery include the following, management of which is discussed in detail separately:
Conditions not treated by delivery -Conditions that are not treated by delivery include:
Need for plasma exchange or anti-complement therapy -Plasma exchange therapy (PEX) is urgent initial treatment for TTP, and anti-complement therapy is urgent initial treatment indicated for C-TMA. TTP and C-TMA can usually be distinguished by the degree of kidney injury. Acute kidney injury with an increasing serum creatinine causing anticipation of dialysis is typical of C-TMA and very rarely occurs in patients with TTP.
PEX and monoclonal antibodies to complement components cannot be initiated simultaneously, unless the monoclonal antibody is repeated daily (instead of weekly) following each PEX procedure, because PEX removes the antibody.
Both PEX and anti-complement therapy carry risks of potentially serious adverse effects and are costly. (See "Acquired TTP: Initial treatment", section on 'Acquired TTP during pregnancy' and "Complement-mediated hemolytic uremic syndrome", section on 'Adverse effects'.) Thus, we reserve PEX and anti-complement therapy for individuals with strong supporting evidence for TTP or C-TMA, respectively [23, 36] . This includes the following features (see "Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Initial evaluation (all patients)'):
MAHA and thrombocytopenia are characteristic features of preeclampsia with severe features, which typically resolves within three days following delivery. Persistence of MAHA and thrombocytopenia for more than three days postpartum is also consistent with TTP or C-TMA, but delivery should not be performed solely to establish this finding and therapy should not be delayed until after delivery if one of these TMAs is strongly suspected.
Decisions regarding the likelihood of TTP and C-TMA may be complex and may require the involvement of multiple specialists. We advise early involvement of the consulting hematologist, nephrologist (if appropriate), and laboratory personnel, as well as the anesthesiologist should these therapies be ineffective and emergent delivery required. These considerations are discussed separately. (See "Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)", section on 'Key distinguishing features among the primary TMA syndromes' and "Complement-mediated hemolytic uremic syndrome", section on 'Clinical manifestations'.)
Need for other medications ITP therapies -The management of ITP during pregnancy is generally the same as ITP in a non-pregnant patient, in that the goal of therapy is to reduce the risk of bleeding, not to normalize the platelet count. In individuals who are not bleeding, therapy to raise the platelet count typically is indicated only if the platelet count is below 20,000 to 30,000/microL or if the patient requires a higher count for an invasive procedure. Therapy may also be appropriate at a higher platelet count if the patient has a history of bleeding at a higher count, or if there are other factors that increase the risk of bleeding [16, 31, 32] . In contrast, some patients with ITP who have persistent platelet counts less than 30,000/microL may not require treatment during pregnancy if they were not receiving it prior to conception, except in preparation for delivery.
Decisions about the need for ITP therapy during pregnancy should be based on maternal indications, as there is no evidence that administration of ITP therapies to the mother increases the fetal platelet count or improves neonatal outcomes. This lack of effect on fetal/neonatal platelet counts is illustrated by the following:
When therapy is indicated, we usually use a glucocorticoid as initial therapy. High-dose dexamethasone (typical dose, 40 mg per day for four days) and prednisone (typical dose, 1 mg/kg per day for two weeks followed by a gradual taper) are both effective; dexamethasone may have fewer adverse effects. (See "Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis", section on 'Glucocorticoids'.)
The choice of glucocorticoid in pregnancy thus depends on whether the goal is to minimize fetal exposure or to treat both the mother and the fetus: Preeclampsia with severe features or HELLP syndrome -(See "Preeclampsia: Management and prognosis" and "HELLP syndrome", section on 'Management'.) • A 2012 Cochrane review identified only a single trial from 1990 that evaluated neonatal platelet counts in pregnancies associated with maternal ITP in which the mothers were randomly assigned to receive or not receive ITP therapy [37] . This trial initially included 41 pregnancies in 38 women randomly assigned to receive betamethasone 1.5 mg daily for two weeks, but only 28 were evaluable [38] . Of these, there were no significant differences in the frequency of neonatal thrombocytopenia in the betamethasone-treated mothers versus controls (seven and six infants; 64 versus 57 percent) or in the frequency of neonatal bleeding (three and two infants; 21 versus 14 percent). All of the bleeding was mild (eg, cephalohematoma associated with forceps use).
• In a retrospective review of 98 pregnancies in which therapy was administered for ITP, approximately half were treated with glucocorticoids and half with intravenous immune globulin (IVIG) [39] . Outcomes were similar with both therapies, including maternal platelet count increases (seen in approximately 40 percent in both groups) and bleeding risks, neonatal platelet counts or bleeding, and method of delivery. There were no maternal deaths or critical maternal bleeding.
• https://www.uptodate.com/contents/thrombocytopenia-in-pregnancy/print?search=%E8%A1%80%E5%B0%8F%E6%9D%BF%E5%87%8F%E5%B0%91%E7%9 IVIG may also be appropriate, either in addition to or instead of a glucocorticoid, especially if there is a need to raise the platelet count more rapidly. If therapy is needed to raise the platelet count prior to delivery or neuraxial anesthesia, it should be initiated approximately one week in advance if possible, to allow time for maximal efficacy and platelet count retesting. The increase in platelet count with IVIG is usually temporary.
Typical times for these therapies to take effect are as follows [32, 41] :
Additional information about the administration and dosing of glucocorticoids and IVIG for ITP is discussed separately. (See "Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis", section on 'First-line therapies'.)
Outcomes in pregnant women with ITP have been described in retrospective studies. In general, the use of any type of therapy to raise the platelet count is reported in 30 to 40 percent of pregnancies, and serious complications are rarely seen [21, 39] . The pediatrician should be informed about the possibility of neonatal thrombocytopenia, which may develop several days after delivery, as discussed below. (See 'Neonatal testing' below.)
We generally avoid splenectomy, rituximab, and thrombopoietin receptor agonists during pregnancy due to concerns about maternal and fetal adverse effects [32] . However, we have used rituximab in pregnant women, and these therapies may be appropriate in selected individuals.
If a woman taking rituximab or a thrombopoietin receptor agonist (eg, romiplostim) becomes pregnant, discussion regarding the necessity of continuing the medication in the setting of limited fetal risk data versus the use of alternative medications should be individualized. (See "Safety of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Rituximab'.) Anticoagulation for HIT -As mentioned above, heparin-induced thrombocytopenia (HIT) is extremely rare in pregnancy. If HIT is suspected or confirmed, all heparin exposure should be eliminated and presumptive therapy with a non-heparin anticoagulant should be initiated. The evaluation and management of HIT, and options for anticoagulation during pregnancy, are discussed in detail separately. (See "Clinical presentation and diagnosis of heparin-induced thrombocytopenia" and "Management of heparin-induced thrombocytopenia" and "Use of anticoagulants during pregnancy and postpartum", section on 'Alternatives to heparin'.) Antibiotics -Broad spectrum antibiotics are appropriate for patients with a presumed infectious cause of thrombocytopenia, either due to severe bacterial infection or DIC.
The choice of antibiotic depends on the site of infection and likely organisms, as discussed in separate topic reviews. As examples:
Neuraxial anesthesia -There is a lack of high-quality data regarding what constitutes a safe platelet count for placement of a neuraxial catheter, and the threshold may differ for different patients and different thrombocytopenic disorders. It is also worth noting that of the numerous pregnant women who have epidural anesthesia without platelet count testing, some will predictably be mildly thrombocytopenic and not counted in case series [46] .
As a general rule, epidural anesthesia is considered to be safe if the platelet count is above 50,000 to 80,000/microL [47] [48] [49] . Depending on the cause and severity of thrombocytopenia, platelet transfusion and/or other therapies may be indicated two or more days prior to placement of a neuraxial catheter.
Practice patterns vary, and it is important to discuss options for neuraxial analgesia or anesthesia with the consulting anesthesiologist prior to delivery in patients with thrombocytopenia. Obstetricians should be familiar with policies at their institution and preferences of the treating anesthesiologist. This subject is discussed in more detail separately. (See "Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Neuraxial analgesia and low platelets'.)
For women with presumed diagnosis of ITP who are near term and have a platelet count just below the "acceptable" limit for regional anesthesia, a brief treatment course with a glucocorticoid such as dexamethasone, 40 mg daily for up to four days in order to increase the patient's platelet count into the acceptable range may be used, with the understanding that there is little evidence to support this practice. Compared with prednisone, dexamethasone has better efficacy in raising the platelet count and fewer adverse effects, and crosses the placenta, which may improve the fetal platelet count (if low) and aid in lung maturation, although either When delivery is not imminent (eg, during early pregnancy and/or when preterm birth is not expected), prednisone is preferable because there is less fetal exposure [40] . (See "Safety of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Glucocorticoids'.)
• If the patient is a candidate for therapy to improve neonatal outcomes related to preterm birth, then dexamethasone or betamethasone given antenatally can serve to treat both preterm birth and ITP. (See "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery".)
• IVIG -1 to 3 days for initial response, 2 to 7 days to peak response.
• Dexamethasone -2 to 14 days for initial response, 4 to 28 days to peak response.
• Prednisone -4 to 14 days for initial response, 7 to 28 days to peak response.
• Immunoglobulins do not cross the placenta until the second trimester, with a linear increase in the amount of transfer as pregnancy progresses [42, 43] . Thus, rituximab therapy in the first trimester should be without adverse effects. Review of a global rituximab drug safety database identified 153 pregnancies associated with rituximab exposure for which outcomes were known. Of these, 90 (59 percent) resulted in live births; 22 (14 percent) were associated with premature birth; 11 neonates (7 percent) had hematologic abnormalities; one neonate died at age six weeks; and two infants had congenital malformations [44] . Of note, most of these pregnancies were confounded by concomitant use of teratogenic agents and other maternal conditions (eg, lymphoma). (See "Safety of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Rituximab'.)
• Splenectomy may be required for a patient with severe thrombocytopenia and bleeding who is unresponsive to glucocorticoids, IVIG, and rituximab, but splenectomy later during pregnancy becomes a greater risk as the uterus becomes larger.
• The safety of thrombopoietin receptor agonists (eg, romiplostim, eltrombopag) during pregnancy is unknown. These agents stimulate platelet production by activating the platelet thrombopoietin receptor; they also may stimulate other hematopoietic cells. Registries have been established by the manufacturers to document pregnancy outcomes when these agents are inadvertently given to pregnant women. (See "Immune thrombocytopenia (ITP) in adults: Second-line and subsequent therapies", section on 'Thrombopoietin receptor agonists' and "Clinical applications of thrombopoietic growth factors".)
• A form of recombinant human thrombopoietin (rhTPO) is available in China. When administered to 31 pregnant women with ITP who had platelet counts <30,000/microL that could not be increased by glucocorticoids, IVIG, or platelet transfusions (ie, treatment-refractory ITP), this rhTPO agent was well tolerated and was not associated with adverse effects in the newborns [45] . Platelet counts normalized in 10 and increased in an additional 13 (overall response rate, 74 percent). 
The range of outcomes from placement of a neuraxial catheter in pregnant women with ITP was illustrated in a retrospective series of 119 pregnant women with ITP over a 10-year period, for whom data on analgesia were available for all but one [21] . Of the 42 women who received epidural anesthesia, none had a complication related to the catheter placement. Platelet counts were <100,000/microL in 19 women (45 percent), <75,000/microL in six women (14 percent), and <50,000/microL in one woman (2 percent).
Neonatal testing -Settings in which testing of the neonatal platelet count is prudent include the following:
The risk of neonatal thrombocytopenia in women with gestational thrombocytopenia (GT) is difficult to determine, as there are no tests that can distinguish GT from ITP, and women in some series may have been misclassified [50] . If we are confident in the diagnosis of GT (eg, if previous pregnancies were associated with maternal thrombocytopenia that resolved after delivery), then we do not routinely obtain a neonatal platelet count. If the diagnosis of GT versus ITP is unclear, it may be reasonable to treat as ITP until further information becomes available.
The overall risk of thrombocytopenia in infants born to mothers with ITP has been estimated to be in the range of 10 to 15 percent; severe thrombocytopenia is possible but much less common. In the series of 119 pregnancies associated with maternal ITP, 31 of 109 infants (28 percent) had platelet counts below 150,000/microL [21] . Of these, six infants (6 percent) had counts <20,000/microL, five had counts between 20,000 and 50,000, and the remainder had counts >50,000/microL. One infant had an intracerebral hemorrhage, which was not clearly due to thrombocytopenia; the infant was born at 29 weeks of a twin gestation, and the platelet count nadir was 135,000/microL on the day after delivery. There were two fetal deaths, one unrelated to thrombocytopenia and one a stillbirth at 27 weeks associated with extensive fetal hemorrhage and severe maternal thrombocytopenia. Smaller series have found similar rates of thrombocytopenia and similar platelet count distributions [51] [52] [53] [54] [55] [56] [57] [58] [59] .
There does not appear to be a strong correlation between maternal platelet count and neonatal platelet count in ITP [21] . Risk factors for neonatal thrombocytopenia include a previous history of neonatal thrombocytopenia, prior splenectomy, severe thrombocytopenia (eg, <50,000/microL) at some point during the pregnancy, and possibly a maternal platelet count <100,000/microL at the time of delivery [21, 51, 54, 55, 60, 61] . As noted above, there is no evidence that ITP therapy for the mother raises the fetal platelet count. (See 'ITP therapies' above.) When neonatal testing is performed, it should be done after delivery, typically by cord blood platelet count using clean venipuncture of a cord vessel rather than draining blood from the cord [31] . Platelet count testing by scalp blood sampling or cordocentesis is not recommended because these procedures are associated with adverse events and have not been demonstrated to improve outcomes. Percutaneous umbilical cord blood sampling carries an increased risk of fetal hemorrhage that is considered to be greater than the risk of severe neonatal intracerebral hemorrhage from thrombocytopenia (approximately 2 percent versus 1 percent) [14, 21, 31, 51, 62] . Fetal scalp blood sampling has been abandoned because it is technically difficult and frequently results in spuriously low platelet counts [14, 16, 31, 51] .
Based on our experience, if the neonate's platelet count is low (<150,000/microL), a repeat platelet count the next day is appropriate to be confident that the platelet count is stable or increasing. The neonatal platelet count may decrease up to several days after birth (typical nadir, between days 2 to 5 postpartum) [53] . The mechanism is thought to involve passage of maternal antiplatelet antibodies to the fetal circulation, with gradual acquisition of infant splenic function within the first few days after birth that leads to destruction of antibody-sensitized platelets. Management of the thrombocytopenic neonate is discussed separately. (See "Clinical manifestations, evaluation, and management of neonatal thrombocytopenia", section on 'Management'.) Postpartum -The patient's postpartum course depends on the cause of thrombocytopenia. In some cases in which the diagnosis was unclear, the postpartum course is helpful in clarifying the diagnosis, and the diagnosis in turn guides postpartum management.
For patients with stable or worsening thrombocytopenia following delivery, diagnostic evaluation should be pursued as done for non-pregnant patients. • Thrombocytopenia is expected to resolve postpartum in women with GT, preeclampsia/HELLP syndrome, and DIC for which the cause has been corrected.
• In GT the maternal platelet count often returns to normal within two to four weeks following delivery but may not be normal until six to eight weeks [13, 63] . We check a platelet count at the six-week postpartum visit, and repeat the count in another one to two weeks only if the six-week count remains low. Recurrence during subsequent pregnancies is not uncommon, typically to a similar platelet count as previously seen [13, 50] .
• In preeclampsia/HELLP, the maternal thrombocytopenia may first occur at or after delivery, but in all women there should be at least a beginning recovery of the platelet count within one to three days postpartum. Of note, the platelet count may initially worsen before it improves. For those with stable preeclampsia and thrombocytopenia, we initially check the platelet count daily until it begins rising and then again at the six-week postpartum visit. For those with HELLP, we check the count every 6 to 12 hours until it begins to show stability or improvement.
• In women with DIC at term, recovery from thrombocytopenia is related to correction of the underlying cause of the DIC. Most causes associated with pregnancy, such as placental abruption, will be corrected by delivery, although others may not be corrected. Sepsis requires appropriate identification of the infectious organism, treatment with antibiotics, and control of the source, with possible surgical removal. We check the platelet count daily (or more often, if clinical features warrant) until it begins to show stability or improvement. The causes of DIC in pregnancy, their management, and expected postpartum course are discussed in more detail separately. (See "Disseminated intravascular coagulation during pregnancy".)
• Thrombocytopenia caused by TTP or C-TMA may worsen or first occur during the postpartum period. We check the maternal platelet count every 6 to 12 hours until it begins to show stability or improvement.
• Thrombocytopenia caused by a condition unrelated to the pregnancy such as an inherited platelet disorder or ITP will be present postpartum.
• Our experience corroborates published reports that show GT often recurs in future pregnancies.
• https://www.uptodate.com/contents/thrombocytopenia-in-pregnancy/print?search=%E8%A1%80%E5%B0%8F%E6%9D%BF%E5%87%8F%E5%B0%91%E7%9 
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